Edition:
India

Celldex Therapeutics Inc (CLDX.OQ)

CLDX.OQ on NASDAQ Stock Exchange Global Select Market

0.69USD
23 Apr 2018
Change (% chg)

-- (--)
Prev Close
$0.69
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
394,684
52-wk High
$3.41
52-wk Low
$0.65

Latest Key Developments (Source: Significant Developments)

Celldex Therapeutics Q3 loss per share $0.20
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Celldex Therapeutics Inc :Q3 revenue $3.9 million versus $2.2 million .Celldex reports third quarter 2017 results.Q3 revenue view $1.1 million -- Thomson Reuters I/B/E/S.Q3 loss per share $0.20.Q3 earnings per share view $-0.27 -- Thomson Reuters I/B/E/S.Celldex Therapeutics Inc - ‍ projects that topline primary endpoint data should be available in Q2 of 2018 for metric​.Celldex therapeutics inc - ‍by year-end, celldex plans to initiate an open-label phase 2 study of CDX-3379 given in combination with erbitux​.  Full Article

COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS 5.1 PCT PASSIVE STAKE IN CELLDEX THERAPEUTICS AS OF DEC 31, 2016
Friday, 10 Feb 2017 

Columbia Wanger Asset Management LLC:COLUMBIA WANGER ASSET MANAGEMENT LLC REPORTS A 5.1 PERCENT PASSIVE STAKE IN CELLDEX THERAPEUTICS INC AS OF DEC 31, 2016 - SEC FILING.  Full Article

Celldex reports second quarter 2016 results
Tuesday, 9 Aug 2016 

Celldex Therapeutics Inc : Q2 revenue $1.4 million versus $2.7 million . Q2 earnings per share view $-0.34 -- Thomson Reuters I/B/E/S . Celldex reports second quarter 2016 results . Q2 loss per share $0.32 .Q2 revenue view $850,000 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Celldex’S Metric Study In Metastatic Triple-Negative Breast Cancer Does Not Meet Primary Endpoint

* CELLDEX’S METRIC STUDY IN METASTATIC TRIPLE-NEGATIVE BREAST CANCER DOES NOT MEET PRIMARY ENDPOINT